Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: Extending the potential of broadly cross-protecting epitopes

Vaccine

Volumn 32, Issue 29, 2014, Pages 3651-3655

  Wibowo, Nani ^a   Hughes, Fiona K ^a   Fairmaid, Emily J ^b   Lua, Linda H L ^a   Brown, Lorena E ^b   Middelberg, Anton P J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Capsomere; E. coli; M2e; Rapid manufacture; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CAPM2EPR8 VACCINE; ESCHERICHIA COLI VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; EPITOPE; IMMUNOLOGICAL ADJUVANT; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; DISEASE SEVERITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; FEMALE; IMMUNOPROPHYLAXIS; INFLUENZA A; INFLUENZA VACCINATION; MASS IMMUNIZATION; MOUSE; NONHUMAN; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS LOAD; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; BLOOD; ESCHERICHIA COLI; GENE VECTOR; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; LUNG; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIGEN PRESENTATION; CROSS PROTECTION; EPITOPES; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84901639455     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.062     Document Type: Article

References (29)

1. Monto A.S. Epidemiology and virology of influenza illness. Am J Managed Care 2000, 6:S255-S264.
2. Webster R.G., Bean W.J., Gorman O.T., Chambers T.M., Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
3. Shapshak P., Chiappelli F., Somboonwit C., Sinnott J. The influenza pandemic of 2009: lessons and implications. Mol Diagn Therapy 2011, 15:63-81.
4. Gao H.-N., Lu H.-Z., Cao B., Du B., Shang H., Gan J.-H., et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013, 368:2277-2285.
5. Lamb R.A. Genes and proteins of the influenza viruses. The Influenza Viruses 1989, 43-47. Plenum Press, New York. R.M. Krug (Ed.).
6. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
7. De Filette M., Martens W., Smet A., Schotsaert M., Birkett A., Londoño-Arcila P., et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008, 26:6503-6507.
8. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
9. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D.A., Tai W., Cramer D.V., et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
10. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y-H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23:366-371.
11. Tissot A.C., Renhofa R., Schmitz N., Cielens I., Meijerink E., Ose V., et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS ONE 2010, 5:e9809.
12. Ohmit S.E., Victor J.C., Rotthoff J.R., Teich E.R., Truscon R.K., Baum L.L., et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006, 355:2513-2522.
13. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
14. Amour S., Voirin N., Regis C., Bouscambert-Duchamp M., Comte B., Coppéré B., et al. Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009). Vaccine 2012, 30:821-824.
15. Andersson A-M.C., Håkansson K.O., Jensen B.A.H., Christensen D., Andersen P., Thomsen A.R., et al. Increased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing protein. PLoS ONE 2012, 7:e46395.
16. Kotlyarov R.Y., Kuprianov V.V., Migunov A.I., Stepanova L.A., Tsybalova L.M., Kiselev O.I., et al. Development of recombinant vaccine against A(H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein. Acta Nat 2010, 2:71-76.
17. Liew M.W.O., Rajendran A., Middelberg A.P.J. Microbial production of virus-like particle vaccine protein at gram-per-litre levels. J Biotechnol 2010, 150:224-231.
18. Choi J.H., Keum K.C., Lee S.Y. Production of recombinant proteins by high cell density culture of Escherichia coli. Chem Eng Sci 2006, 61:876-885.
19. Wibowo N., Chuan Y.P., Lua L.H.L., Middelberg A.P.J. Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 2013, 103:12-20.
20. Chuan Y.P., Lua L.H.L., Middelberg A.P.J. High-level expression of soluble viral structural protein in Escherichia coli. J Biotechnol 2008, 134:64-71.
21. Lipin D.I., Raj A., Lua L.H.L., Middelberg A.P.J. Affinity purification of viral protein having heterogeneous quaternary structure: modeling the impact of soluble aggregates on chromatographic performance. J Chromatogr A 2009, 1216:5696-5708.
22. Pejoski D., Zeng W., Rockman S., Brown L.E., Jackson D.C. A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunol Cell Biol. 2010, 88:605-611.
23. Chuan Y.P., Rivera-Hernandez T., Wibowo N., Connors N.K., Wu Y., Hughes F.K., et al. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 2013, 110:2343-2351.
24. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
25. Lamb R.A., Zebedee S.L., Richardson C.D. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985, 40:627-633.
26. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172:5598-5605.
27. El Bakkouri K., Descamps F., De Filette M., Smet A., Festjens E., Birkett A., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 2011, 186:1022-1031.
28. Grandea A.G., Olsen O.A., Cox T.C., Renshaw M., Hammond P.W., Chan-Hui P-Y., et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci 2010, 107:12658-12663.
29. Song J-M., Wang B-Z., Park K-M., Van Rooijen N., Quan F-S., Kim M-C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS ONE 2011, 6:e14538.